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Abstract 
Review on CX3CL1, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: ABCD-3, C3Xkine, CXC3, CXC3C, 
NTN, NTT, SCYD1, fractalkine, neurotactin 




CX3CL1 gene is located on the long arm of  
chromosome 16 at position 13 and contains three 
exons. This gene encodes for a protein of 397 aa. 
The first 24 aa represents the peptide signal. 
Transcription 
Only one type of transcript has been described.  
The 1194-nucleotide transcript encodes a protein of 
397 amino acid residues.  
The primary structure of human CX3CL1 consists 
of an N-terminal 24-amino acid signal sequence 
followed by the chemokine domain of CX3CL1, a 
mucin-like stalk, a transmembrane domain and an 
intracellular part. 
Pseudogene 
None described so far. 
 




The CX3CL1 gene comprises 3 exons. The first codes for the peptide signal. 
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CX3CL1 is synthesized as a membrane protein 
consisting of the chemokine domain, a highly 
glycosylated mucin-like stalk, a transmembrane 
domain and an intracellular part. Cleavage by some 
metalloproteinases like ADAM-10 (Hundhausen et 
al., 2003), ADAM-17 (Garton et al., 2001; Tsou et 
al., 2001), MMP-2 (Bourd-Boittin et al., 2009) and 
cathepsin-S (Clark et al., 2009) gives raise to the 
soluble form of CX3CL1 consisting of the 
chemokine domain and the glycosylated mucin-like 
stalk (Bazan et al., 1997; Schulte et al., 2007). The
C-terminal part contains two putative adaptor 
protein-2 (AP-2)-binding motifs, that control the 
constitutive endocytosis of the whole protein 
(Huang et al., 2009) mediated by clathrin and 
dynamin-1 (Robinson et al., 2002). 
Expression 
The chemokine CX3CL1 is constituvely expressed 
in microglial cells (Cross and Woodroofe, 1999), 
astrocytes (Hatori et al., 2002) and some neurons 
(Harrison et al., 1998; Cross and Woodroofe, 1999; 
Maciejewski-Lenoir et al., 1999; Deiva et al., 
2004). Its expression is stimulated by inflammatory 
ligands in vascular endothelial cells (Fong et al.,
1998; Imaizumi et al., 2000; Fraticelli et al., 2001; 
Schäfer et al., 2007), renal endothelial (Cross and 
Woodroofe, 1999) and epithelial cells (Chakravorty 
et al., 2002), in aortic (Ludwig et al., 2002; Ollivier 
et al., 2003) and pulmonary (Sukkar et al., 2004) 
smooth muscle cells and in dendritic cells 
(Papadopoulos et al., 1999; Dichmann et al., 2001; 
Pallandre et al., 2008). 
Localisation 
The chemokine CX3CL1 is mainly localized at the 
plasma membrane (Bazan et al., 1997; Fong et al., 
2000). Its biosynthesis in the Golgi and/or ER 
organelles starts as an non glycosylated and 
intracellular. 
Function 
The function of CX3CL1 relies on both of its 
forms: the soluble form, released by 
metalloproteinases, is chemoattractant while the 
membrane form mediates stable adhesion of 
leukocytes such as integrins (Fong et al., 1998; 




Both CX3CL1 and CX3CR1 are expressed in 
human surgical glioma samples. The expression of 
CX3CL1 was inversely correlated with patient 
overall survival (Erreni et al., 2010). The presence 
of the rare variant CX3CR1 was shown to be 




The CX3CL1 molecule, with its unique CX3CR1 
receptor (Imai et al., 1997), has been shown to be 
central in cellular processes leading to 
atherosclerosis. In animal models, the deletion of 
CX3CR1 genes lead to decreased disease 
(Combadière et al., 2003; Lesnik et al., 2003). In 
human, the presence of the rare variant CX3CR1 
I249 is an independent genetic risk factor for 
coronary artery disease (Moatti et al., 2001). 
Neurotoxicity 
Note 
By binding to its receptor CX3CR1, the CX3CL1 
molecule decreases the microglial neurotoxicity 
mediated by inflammatory molecules (reactive 
species, matrix metalloproteinase, inflammatory 
cytokines) (Cardona et al., 2006). CX3CL1 acts by 
binding to CX3CR1 present on microglia to 
modulate microglial activation (Cho et al., 2011). 
However converse data also exist. During focal 
cerebral ischemia, elimination of CX3CL1 
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signaling was associated with smaller infarct and 
enhanced recovery (Dénes et al., 2008). 
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